Literature DB >> 26167065

Recent developments in the pathophysiology of irritable bowel syndrome.

Magdy El-Salhy1.   

Abstract

Irritable bowel syndrome (IBS) is a common gastrointestinal disorder, the pathophysiology of which is not completely known, although it has been shown that genetic/social learning factors, diet, intestinal microbiota, intestinal low-grade inflammation, and abnormal gastrointestinal endocrine cells play a major role. Studies of familial aggregation and on twins have confirmed the heritability of IBS. However, the proposed IBS risk genes are thus far nonvalidated hits rather than true predisposing factors. There is no convincing evidence that IBS patients suffer from food allergy/intolerance, with the effect exerted by diet seemingly caused by intake of poorly absorbed carbohydrates and fiber. Obesity is a possible comorbidity of IBS. Differences in the microbiota between IBS patients and healthy controls have been reported, but the association between IBS symptoms and specific bacterial species is uncertain. Low-grade inflammation appears to play a role in the pathophysiology of a major subset of IBS, namely postinfectious IBS. The density of intestinal endocrine cells is reduced in patients with IBS, possibly as a result of genetic factors, diet, intestinal microbiota, and low-grade inflammation interfering with the regulatory signals controlling the intestinal stem-cell clonogenic and differentiation activities. Furthermore, there is speculation that this decreased number of endocrine cells is responsible for the visceral hypersensitivity, disturbed gastrointestinal motility, and abnormal gut secretion seen in IBS patients.

Entities:  

Keywords:  Diet; Endocrine cells; Genetic factors; Low-grade inflammation; Microbiota; Stem cells

Mesh:

Substances:

Year:  2015        PMID: 26167065      PMCID: PMC4491952          DOI: 10.3748/wjg.v21.i25.7621

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  296 in total

Review 1.  The intestinal stem cell.

Authors:  Nick Barker; Marc van de Wetering; Hans Clevers
Journal:  Genes Dev       Date:  2008-07-15       Impact factor: 11.361

Review 2.  Peripheral mechanisms in irritable bowel syndrome.

Authors:  Michael Camilleri
Journal:  N Engl J Med       Date:  2012-10-25       Impact factor: 91.245

3.  Association of symptoms with gastrointestinal microbiota in irritable bowel syndrome.

Authors:  Erja Malinen; Lotta Krogius-Kurikka; Anna Lyra; Janne Nikkilä; Anne Jääskeläinen; Teemu Rinttilä; Terttu Vilpponen-Salmela; Atte Johannes von Wright; Airi Palva
Journal:  World J Gastroenterol       Date:  2010-09-28       Impact factor: 5.742

4.  Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis.

Authors:  L-H Wang; X-C Fang; G-Z Pan
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

5.  Molecular forms of human enteroglucagon in tissue and plasma: plasma responses to nutrient stimuli in health and in disorders of the upper gastrointestinal tract.

Authors:  M A Ghatei; L O Uttenthal; N D Christofides; M G Bryant; S R Bloom
Journal:  J Clin Endocrinol Metab       Date:  1983-09       Impact factor: 5.958

6.  Reduction in duodenal endocrine cells in irritable bowel syndrome is associated with stem cell abnormalities.

Authors:  Magdy El-Salhy; Jan Gunnar Hatlebakk; Trygve Hausken
Journal:  World J Gastroenterol       Date:  2015-08-28       Impact factor: 5.742

7.  A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function.

Authors:  Maria I Vazquez-Roque; Michael Camilleri; Thomas Smyrk; Joseph A Murray; Eric Marietta; Jessica O'Neill; Paula Carlson; Jesse Lamsam; Denise Janzow; Deborah Eckert; Duane Burton; Alan R Zinsmeister
Journal:  Gastroenterology       Date:  2013-01-25       Impact factor: 22.682

8.  The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors.

Authors:  Kwang Jae Lee; Yeong Bae Kim; Jang Hee Kim; Hoek Chun Kwon; Dong Kyu Kim; Sung Won Cho
Journal:  J Gastroenterol Hepatol       Date:  2008-11       Impact factor: 4.029

9.  Dietary intakes in people with irritable bowel syndrome.

Authors:  Elizabeth A Williams; Xuili Nai; Bernard M Corfe
Journal:  BMC Gastroenterol       Date:  2011-02-03       Impact factor: 3.067

10.  Celiac and Non-Celiac Forms of Gluten Sensitivity: Shifting Paradigms of an Old Disease.

Authors:  Karol Sestak; Ilana Fortgang
Journal:  Br Microbiol Res J       Date:  2013-10
View more
  31 in total

1.  The CCL28 levels are elevated in the serum of patients with irritable bowel syndrome and associated with the clinical symptoms.

Authors:  Farshad Sheikhesmaili; Ali Jalili; Elmira Taghizadeh; Shohreh Fakhari; Khashaiar Jalili; Ebrahim Ghaderi; Ezatollah Rahimi
Journal:  Am J Clin Exp Immunol       Date:  2021-02-15

Review 2.  Quantitative Risk-Benefit Analysis of Probiotic Use for Irritable Bowel Syndrome and Inflammatory Bowel Disease.

Authors:  William E Bennett
Journal:  Drug Saf       Date:  2016-04       Impact factor: 5.606

Review 3.  Close association between intestinal microbiota and irritable bowel syndrome.

Authors:  W-T Fan; C Ding; N-N Xu; S Zong; P Ma; B Gu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-08-07       Impact factor: 3.267

Review 4.  Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practice.

Authors:  Susan Lucak; Lin Chang; Albena Halpert; Lucinda A Harris
Journal:  Therap Adv Gastroenterol       Date:  2016-09-16       Impact factor: 4.409

5.  Assessment of Anti-vinculin and Anti-cytolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel Syndrome.

Authors:  Ali Rezaie; Sung Chul Park; Walter Morales; Emily Marsh; Anthony Lembo; Jae Hak Kim; Stacy Weitsman; Kathleen S Chua; Gillian M Barlow; Mark Pimentel
Journal:  Dig Dis Sci       Date:  2017-04-27       Impact factor: 3.199

6.  Fecal microbiota transplantation in the treatment of irritable bowel syndrome: a single-center prospective study in Japan.

Authors:  Motonobu Hamazaki; Tsunaki Sawada; Takeshi Yamamura; Keiko Maeda; Yasuyuki Mizutani; Eri Ishikawa; Satoshi Furune; Kenta Yamamoto; Takuya Ishikawa; Naomi Kakushima; Kazuhiro Furukawa; Eizaburo Ohno; Takashi Honda; Hiroki Kawashima; Masatoshi Ishigami; Masanao Nakamura; Mitsuhiro Fujishiro
Journal:  BMC Gastroenterol       Date:  2022-07-14       Impact factor: 2.847

7.  Sleep Dysfunction and Gastrointestinal Diseases.

Authors:  Vikesh Khanijow; Pia Prakash; Helene A Emsellem; Marie L Borum; David B Doman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-12

Review 8.  The role of diet in the pathophysiology and management of irritable bowel syndrome.

Authors:  Magdy El-Salhy; Tanisa Patcharatrakul; Sutep Gonlachanvit
Journal:  Indian J Gastroenterol       Date:  2021-03-05

9.  The Effects of Fecal Microbiota Transplantation on the Symptoms and the Duodenal Neurogenin 3, Musashi 1, and Enteroendocrine Cells in Patients With Diarrhea-Predominant Irritable Bowel Syndrome.

Authors:  Tarek Mazzawi; Magdy El-Salhy; Gülen Arslan Lied; Trygve Hausken
Journal:  Front Cell Infect Microbiol       Date:  2021-05-12       Impact factor: 5.293

10.  Fecal microbiota transplantation for irritable bowel syndrome: An intervention for the 21st century.

Authors:  Magdy El-Salhy; Tanisa Patcharatrakul; Sutep Gonlachanvit
Journal:  World J Gastroenterol       Date:  2021-06-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.